Avadel Pharmaceuticals (AVDL) Share-based Compensation: 2011-2022
Historic Share-based Compensation for Avadel Pharmaceuticals (AVDL) over the last 8 years, with Dec 2022 value amounting to $1.9 million.
- Avadel Pharmaceuticals' Share-based Compensation fell 30.78% to $1.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $7.0 million, marking a year-over-year decrease of 20.95%. This contributed to the annual value of $20.4 million for FY2024, which is 28.94% up from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Share-based Compensation of $1.9 million as of Q4 2022, which was up 0.21% from $1.9 million recorded in Q3 2022.
- Avadel Pharmaceuticals' 5-year Share-based Compensation high stood at $2.8 million for Q3 2018, and its period low was -$229,000 during Q3 2019.
- Moreover, its 3-year median value for Share-based Compensation was $1.8 million (2021), whereas its average is $1.6 million.
- Per our database at Business Quant, Avadel Pharmaceuticals' Share-based Compensation tumbled by 108.09% in 2019 and then spiked by 1,298.18% in 2020.
- Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Share-based Compensation stood at $662,000 in 2018, then slumped by 48.34% to $342,000 in 2019, then skyrocketed by 278.36% to $1.3 million in 2020, then skyrocketed by 115.15% to $2.8 million in 2021, then crashed by 30.78% to $1.9 million in 2022.
- Its Share-based Compensation was $1.9 million in Q4 2022, compared to $1.9 million in Q3 2022 and $658,000 in Q2 2022.